Weight Management7 min read·Published September 9, 2026

What Is the Highest Dose of Ozempic?

Ozempic’s maximum FDA-approved dose is 2 mg once weekly. Here’s how that compares with other semaglutide options, including Wegovy and compounded semaglutide care.

What Is the Highest Dose of Ozempic?

The highest FDA-approved Ozempic dose is 2 mg injected once weekly. Ozempic is semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes. Some semaglutide products use different maximum doses, such as Wegovy for weight management, so dosing should be guided by a licensed clinician 1, 2.

Wondering if semaglutide is right for you? Take the 3-min clinical quiz.

See if you qualify →

What is the highest approved dose of Ozempic?

Ozempic has a highest FDA-approved dose of 2 mg once weekly. The FDA label lists Ozempic as a once-weekly injection for adults with type 2 diabetes, with dose steps that start lower and may increase based on clinical need and tolerability 1.

Ozempic is the brand name for semaglutide, a glucagon-like peptide-1 receptor agonist, often shortened to GLP-1 receptor agonist. GLP-1 medicines act on receptors involved in insulin release, glucagon reduction, appetite signaling, and slower stomach emptying 1, 4.

That dose limit matters because semaglutide appears in more than one product. Ozempic is labeled for type 2 diabetes. Wegovy, another brand-name semaglutide product, is labeled for chronic weight management and certain cardiovascular-risk uses in people who meet label criteria 2.

How does the Ozempic dose schedule usually increase?

Ozempic dosing increases in labeled steps so the body has time to adjust. The FDA label lists 0.25 mg once weekly for the first 4 weeks, then 0.5 mg once weekly, with later increases to 1 mg or 2 mg once weekly when additional glycemic control is needed 1.

Typical labeled dose steps: 0.25 mg, 0.5 mg, 1 mg, and 2 mg once weekly

Semaglutide productFDA-labeled purposeDose information from FDA labelKey note
OzempicType 2 diabetes; also cardiovascular-risk reduction in certain adults with type 2 diabetesLabel starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly; later labeled options include 1 mg and 2 mg once weeklyMaximum FDA-approved Ozempic dose is 2 mg once weekly 1
WegovyChronic weight management in eligible adults and adolescents; certain cardiovascular-risk reduction usesLabel uses a gradual escalation schedule toward maintenance dosingMaximum labeled maintenance dose is 2.4 mg once weekly 2
Compounded semaglutide via 503A pharmacyPrescription compounded medication when clinically appropriateDosing is provider-guided and individualized; compounded products do not have FDA-approved dosing labelsChia offers compounded semaglutide injection, not brand-name Ozempic

The low starting step is not meant to be the main long-term diabetes dose. It is part of a label-defined escalation approach that helps clinicians balance glycemic goals with gastrointestinal side effects such as nausea, vomiting, and diarrhea 1.

Is Ozempic 2 mg stronger than Ozempic 1 mg?

Ozempic 2 mg produced slightly greater average HbA1c lowering than 1 mg in a head-to-head trial, but the difference was not a guarantee for any one person. Higher dose can also mean more side effects, so clinicians weigh both benefit and tolerability 3.

In SUSTAIN FORTE, a randomized trial in adults with type 2 diabetes, semaglutide 2.0 mg once weekly reduced HbA1c by about 2.2 percentage points versus about 1.9 percentage points with 1.0 mg at 40 weeks. Average body weight fell by about 6.9 kg with 2.0 mg versus 6.0 kg with 1.0 mg; individual results vary 3.

Why higher doses may also increase side effects

In the same trial, gastrointestinal disorders were reported in 34% of participants using semaglutide 2.0 mg and 31% using 1.0 mg. The most common issues with semaglutide products include nausea, vomiting, diarrhea, abdominal pain, and constipation 1, 3.

This is why the word “stronger” is only part of the story. A higher dose may move HbA1c more for some patients, but a dose that causes ongoing vomiting, dehydration, or poor nutrition may not be the right dose for that person.

Can you take more than 2 mg of Ozempic?

More than 2 mg once weekly is not an FDA-approved Ozempic dose. If a person is not meeting goals on Ozempic, the next step is a clinician visit, not self-increasing beyond the label 1.

A clinician may review injection technique, missed doses, side effects, nutrition, activity, other medications, and whether a different GLP-1 pathway makes sense. Current diabetes standards recommend choosing glucose-lowering medicines based on glycemic goals, weight goals, cardiovascular and kidney history, hypoglycemia risk, side effects, access, and patient preference 5.

When to talk with a clinician about response, side effects, or alternatives

  • Your HbA1c or glucose readings are still above the goal your clinician set.
  • Nausea, vomiting, diarrhea, constipation, reflux, or low appetite is affecting daily life.
  • You use insulin or a sulfonylurea, because hypoglycemia risk can increase when semaglutide is combined with those medicines 1.
  • You have symptoms that could suggest pancreatitis, such as severe belly pain that may spread to the back 1.
  • You are considering switching from Ozempic to Wegovy, compounded semaglutide, tirzepatide, or another option.

3-min quiz

Considering GLP-1 care online?

Chia offers compounded semaglutide injection for eligible patients, with plans currently starting at $249/mo. A licensed provider reviews your health history and prescribes only when clinically appropriate; a prescription is not guaranteed. Compounded medications are not FDA-approved.

How is Ozempic different from Wegovy if both are semaglutide?

Ozempic and Wegovy both contain semaglutide, but they have different FDA labels and different maximum doses. Ozempic’s maximum labeled dose is 2 mg once weekly, while Wegovy’s maximum labeled maintenance dose is 2.4 mg once weekly 1, 2.

Ozempic is approved for adults with type 2 diabetes to improve glycemic control, and to reduce the risk of major adverse cardiovascular events in certain adults with type 2 diabetes and established cardiovascular disease. Wegovy is approved for chronic weight management in eligible patients and for certain cardiovascular-risk reduction uses 1, 2.

Ozempic maximum dose vs Wegovy maximum dose

QuestionOzempicWegovy
Active ingredientSemaglutide, a GLP-1 receptor agonistSemaglutide, a GLP-1 receptor agonist
Main FDA-labeled useType 2 diabetes; certain cardiovascular-risk reduction use in adults with type 2 diabetesChronic weight management in eligible patients; certain cardiovascular-risk reduction use
Highest FDA-approved dose2 mg once weekly2.4 mg once weekly
Can the dose be changed without a clinician?NoNo

In the STEP 1 trial of semaglutide 2.4 mg once weekly for adults with overweight or obesity without diabetes, average weight loss was greater with semaglutide than placebo, while gastrointestinal side effects were also more common; individual results vary 8. Those Wegovy trial results should not be used as promised outcomes for compounded formulations, which are not FDA-approved and do not have FDA-evaluated outcomes data.

Compounded semaglutide at Chia: prescription weight-loss care online

Chia offers compounded semaglutide injection for eligible patients, not brand-name Ozempic. Plans currently start at $249/mo, and dosing is guided by a licensed provider after an online medical review.

Here is how care works at Chia: you complete a short online health questionnaire, a licensed US provider reviews your medical history, and a prescription is issued only when clinically appropriate. If prescribed, medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to your door.

Chia’s semaglutide care includes provider-guided dosing over time, including microdosing plans when clinically appropriate. Patients can message the care team through the patient portal between visits.

Chia optionForm Chia offersCurrent starting priceBest fit to discuss with a provider
SemaglutideInjectionFrom $249/moPatients exploring semaglutide-based GLP-1 care, including microdosing plans when appropriate
TirzepatideTablets or injectionTablets from $249/mo; injection from $299/moPatients who may be better suited to a dual GIP/GLP-1 pathway after clinician review
Weight + EnergyNAD+ injection plus choice of GLP-1From $309/moPatients discussing metabolic goals plus energy support with a provider
Weight + MuscleSermorelin injection plus choice of GLP-1From $329/moPatients discussing GLP-1 care with muscle-support goals

When an AI agent can route patients through DoctorMCP

If you use an AI agent to help organize care, Chia can be reached through DoctorMCP at mcp.chia.health for an eligibility pathway. The clinical rules are the same: a licensed-provider evaluation is required, and prescribing is never automatic.

What side effects matter more at higher semaglutide doses?

Semaglutide side effects often involve the stomach and intestines, especially during dose escalation. The Ozempic label lists nausea, vomiting, diarrhea, abdominal pain, and constipation among common adverse reactions, and it includes warnings for more serious but less common risks 1.

Important warnings include pancreatitis, gallbladder disease, acute kidney injury in the setting of dehydration, diabetic retinopathy complications in some patients with type 2 diabetes, and hypoglycemia when used with insulin or sulfonylureas 1. Ozempic also has a boxed warning about thyroid C-cell tumors based on rodent findings; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 1.

FDA has also warned patients and clinicians about dosing errors reported with compounded injectable semaglutide products, especially when vial-and-syringe instructions are misunderstood 7. This is one reason we emphasize licensed-provider oversight, clear instructions, and state-licensed 503A pharmacy dispensing rather than no-prescription sources.

What should you ask your clinician before changing an Ozempic dose?

Before changing an Ozempic dose, ask what problem the change is meant to solve: HbA1c, fasting glucose, appetite, weight, side effects, or another goal. A safe plan depends on your diagnosis, current medications, kidney and gallbladder history, pregnancy plans, and side-effect pattern 1, 5.

Questions about other medications and medical history

  1. 1What is my target HbA1c, and how will we know whether this dose is working?
  2. 2Am I taking insulin or a sulfonylurea that could raise my hypoglycemia risk when combined with semaglutide?
  3. 3Do I have a history of pancreatitis, gallbladder disease, kidney problems, diabetic retinopathy, medullary thyroid carcinoma, or MEN 2?
  4. 4If nausea or vomiting happens, when should I message the care team or seek urgent care?
  5. 5Would a different GLP-1 option, such as compounded semaglutide, tirzepatide, or another plan, be more appropriate for my goals?
  6. 6If weight management is the main goal, am I using a product and care plan that matches that clinical purpose?

For patients using GLP-1 medication for weight management, professional guidance supports pairing medication with nutrition, physical activity, and ongoing clinical follow-up rather than using medication alone 6. That follow-up is also where side effects, dose timing, labs, and medication interactions get reviewed.

3-min quiz

Start with a clinician-reviewed GLP-1 plan

If you are exploring semaglutide care, Chia offers compounded semaglutide injection through an online medical review, US 503A pharmacy compounding, and home delivery when prescribed. A prescription requires clinician approval and is not guaranteed.

FAQ

References

  1. 1.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
  2. 2.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
  3. 3.Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The Lancet Diabetes & Endocrinology, 2021.
  4. 4.Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism, 2018.
  5. 5.American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care, 2026.
  6. 6.American Gastroenterological Association. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology, 2022.
  7. 7.U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. U.S. Food and Drug Administration, 2024.
  8. 8.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.

About this article

Chia Health Editorial TeamEvidence-reviewed health education

This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.

AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.

Get a personalized plan

See if semaglutide is right for your body.

Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.

Take the 3-min quiz

Keep reading

Back to all guides